Know Labs, Inc. focuses on the development and commercialization of proprietary technologies in the United States. Its technology uses spectroscopy to direct electromagnetic energy through a substance or material to capture a molecular signature. The company refers to its technology as Bio-RFID. The Bio-RFID technology can be integrated into various wearable, mobile, or bench-top form factors. Its first application of Bio-RFID technology is a product marketed as a glucose monitor that provide the user with real time information on their blood glucose levels. The company was formerly known as Visualant, Incorporated and changed its name to Know Labs, Inc. in May 2018. Know Labs, Inc. was founded in 1998 and is headquartered in Seattle, Washington.

Know Labs, Inc.

Know Labs uses non-invasive diagnostic technology to identify and measure a variety of molecules using radio waves.

Know Labs

Know Labs, Inc. | 2,947 followers on LinkedIn. Transforming Non-Invasive Medical Diagnostics | Know Labs is transforming non-invasive medical diagnostics. The proprietary technology platform uses radiofrequency (RF) dielectric spectroscopy and can be integrated into a variety of wearable, mobile, or bench-top form factors. The first application is a non-invasive continuous blood glucose monitoring device that will provide the user with real-time information on their blood glucose levels, assisting billions of people with diabetes and prediabetes to manage this medical condition.

Ron Erickson

Chief Financial Officer & Senior Vice President, Intellectual Property (IP), Know Labs (NYSE: KNW)

Peter Conley

Karmeen Kulkarni

CMO @Know Labs ($KNW) I Mama to Izzy I Ex-Oura, Dropbox, Electronic Arts I Brand Builder I Board Member

Jessica English

New update --> Our team is exploring a great growth opportunity. More to come soon. https://lnkd.in/gpixsQfD

Today, Know Labs announced the publication of our peer-reviewed study in the esteemed Diabetes Technology and Therapeutics Journal. The study demonstrates the accuracy of our proprietary radiofrequency (RF) dielectric sensor in classifying an individual’s glycemic status—serving as proof-of-concept for a novel, non-invasive screening device. We are incredibly proud of the team involved with producing these results and remain committed to developing accurate, affordable, and accessible solutions for the 500M+ people worldwide living with diabetes and the 240M+ people worldwide remaining undiagnosed. See the published article here: https://lnkd.in/gHch98X6

Today Know Labs led an interactive discussion during Friends For Life Orlando 2024 where we imagined a world with a no-needle CGM. Thank you Children With Diabetes for having us and for continuing to support our mission to deliver the first FDA-cleared non-invasive CGM to the marketplace. A very special thank-you to all those who participated in the discussion by sharing your stories, asking thoughtful questions, and helping us ensure we get it right. #FFLOrlando24

This article in CNET featured Know Labs as one company working to develop a truly no-needle device that can accurately measure blood glucose. The article covered our recent clinical results presentation at the American Diabetes Association 's 84th Scientific Sessions, the platform nature of our proprietary radiofrequency (RF) technology, and the impact non-invasive medical diagnostics could have on predictive health. Read the full article here: https://lnkd.in/gTsvcNtJ #medicaldevice #glucosemonitoring #CGM

Today we announced that we’ve been selected for an abstract poster presentation at the American Diabetes Association ’s (ADA) 84th Scientific Sessions in Orlando, Florida on Saturday, June 22, 2024 at 12:30 p.m. - 1:30 p.m. EDT. For those attending, Dr. Virend K. Somers of the Mayo Clinic will be presenting the abstract titled, “A New Machine Learning Model and Expanded Dataset for a Non-Invasive BGM.” These interim study results are the latest from our clinical research protocol involving participants with pre-diabetes and T2D, using venous blood as a comparative reference. The results demonstrate a stable MARD with more than twice as much data collected from 22 participants and a new machine learning model. See the full announcement here: https://lnkd.in/gRZqPWeX #ADASciSessions

We're excited to share that Know Labs, Inc. has joined the Wyss Diagnostic Accelerator (DxA)'s Industrial Participant Program(IPP). They are the twentieth IPP member, joining other companies with a range of diagnostically relevant expertise. The Wyss DxA IPP serves as a collaboration hub between healthcare testing companies, and the scientific and clinical community within the Wyss Institute, as well as our affiliated institutions and the broader Harvard ecosystem. https://bit.ly/3z0TWBw

Wyss Institute at Harvard University

Great event, lots of new connections! Thank you BIO International Convention .

Leo Trautwein

Today we announced that we've joined the renowned Industrial Participant Program of the Wyss Institute at Harvard University 's Diagnostics Accelerator. As a member, Know Labs joins other leaders dedicated to accelerating the development of disruptive, innovative solutions that address urgent and unmet clinical needs. We'll contribute experience in developing novel radiofrequency (RF) dielectric sensor technology for applications in non-invasive blood glucose monitoring for diabetes management, as well as for broader medical diagnostic applications. See more in a release here: https://lnkd.in/gbhtq_5w

It was my pleasure to show Know Labs, Inc. progress at Hospitalar 2024, as part of the State of Washington’s delegation. Thank you all that stopped by and see you again in 2025. … And Sidera for organizing it.

	Sep '14	Sep '15	Sep '16	Sep '17	Sep '18	Sep '19	Sep '20	Sep '21
net income	-1.02M -	-2.63M 158.63%	-1.75M 33.62%	-3.90M 123.37%	-3.26M 16.50%	-7.61M 133.68%	-13.56M 78.17%	-25.36M 86.99%
depreciation and amortization	418.27K -	353.23K 15.55%	178.76K 49.39%	81.28K 54.53%	132.62K 63.15%	259.35K 95.56%	242.99K 6.31%	200.81K 17.36%
deferred income tax		-30K -
stock based compensation	178.55K -	202.96K 13.67%	441.22K 117.39%	37.85K 91.42%	290.58K 667.75%	1.26M 333.32%	1.70M 35.18%	3.58M 110.09%
change in working capital	457.08K -	1.68M 268.59%	-671.44K 139.85%	239.81K 135.72%	205.37K 14.36%	189.25K 7.85%	283.19K 49.64%	808.75K 185.58%
accounts receivables	191.58K -	167.34K 12.65%	-189.11K 213.00%	-20.58K 89.12%	362.04K 1,858.99%	257.49K 28.88%	63.05K 75.51%
inventory	87.96K -	195.01K 121.70%	-77.39K 139.69%	69.31K 189.55%	22.33K 67.79%	196.48K 780.01%	7.10K 96.38%
accounts payables	144.81M -	1.29M 99.11%	-406.39M 31,611.11%	127.18K 100.03%	-171.05K 234.49%	-208.76K 22.05%	224.45K 207.52%	797.34M 355,135.62%
other working capital	-144.63M -	32.72K 100.02%	405.99M 1,240,849.58%	63.90K 99.98%	-7.94K 112.43%	-55.96K 604.51%	-11.41K 79.60%	-796.53M 6,978,419.80%
other non cash items	-1.42M -	180.22K 112.73%	-1.58M 974.39%	2.28M 244.56%	1.51M 33.63%	2.80M 85.23%	7.42M 164.97%	13.92M 87.64%
net cash provided by operating activities	-1.38M -	-239.88K 82.61%	-3.37M 1,306.44%	-1.26M 62.52%	-1.12M 11.64%	-3.10M 177.86%	-3.91M 26.09%	-6.85M 75.04%
investments in property plant and equipment			-23.44K -	2.44M 10,515.16%		-79.93K -	-70.13K 12.26%	-299.52K 327.08%
acquisitions net
purchases of investments					-97.25K -
sales maturities of investments
other investing activites	29.30K -	21.45K 26.78%	6.58K 69.30%	-2.41M 36,654.67%
net cash used for investing activites	29.30K -	21.45K 26.78%	-16.85K 178.56%	33.88K 301.01%	-97.25K 387.09%	-79.93K 17.81%	-70.13K 12.26%	-299.52K 327.08%
debt repayment	-264.06K -	-292.69K 10.84%	-580.09K 98.19%	-125K 78.45%	-420.54K 236.43%	-92.09K 78.10%
common stock issued	91M -		2.88M -	550K 80.92%	1.75M 218.18%	348.90M 19,837.14%	125K 99.96%	202.82M 162,156%
common stock repurchased			-505K -
dividends paid
other financing activites	-90.06M -	523K 100.58%	1.70M 224.92%	720.32K 57.61%	716.15K 0.58%	-344.66M 48,226.64%	6.26M 101.82%	-187.71M 3,100.34%
net cash used provided by financing activities	673.35K -	230.31K 65.80%	3.50M 1,418.26%	1.15M 67.24%	2.05M 78.61%	4.15M 102.89%	6.38M 53.75%	15.11M 136.79%
effect of forex changes on cash
net change in cash	-676.74K -	11.88K 101.76%	106.04K 792.62%	-85.13K 180.28%	831.23K 1,076.44%	966.43K 16.27%	2.40M 148.06%	7.96M 232.04%
cash at beginning of period	747.13K -	70.39K 90.58%	82.27K 16.88%	188.31K 128.90%	103.18K 45.21%	934.41K 805.60%	1.90M 103.43%	4.30M 126.12%
cash at end of period	70.39K -	82.27K 16.88%	188.31K 128.90%	103.18K 45.21%	934.41K 805.60%	1.90M 103.43%	4.30M 126.12%	12.26M 185.20%
operating cash flow	-1.38M -	-239.88K 82.61%	-3.37M 1,306.44%	-1.26M 62.52%	-1.12M 11.64%	-3.10M 177.86%	-3.91M 26.09%	-6.85M 75.04%
capital expenditure			-23.44K -	2.44M 10,515.16%		-79.93K -	-70.13K 12.26%	-299.52K 327.08%
free cash flow	-1.38M -	-239.88K 82.61%	-3.40M 1,316.21%	1.18M 134.64%	-1.12M 194.94%	-3.18M 185.01%	-3.98M 25.12%	-7.15M 79.48%

CO:KNOWLABS

Know Labs

Last Close

2.62

16/09 04:00

Market Cap

34.17M

Beta: -

Volume Today

409.44K

Avg: -

Preview